Literature DB >> 10951203

Interaction of antimony tartrate with the tripeptide glutathione implication for its mode of action.

H Sun1, S C Yan, W S Cheng.   

Abstract

The tripeptide glutathione (gamma-L-Glu-L-Cys-Gly, GSH) is thought to play an important role in the biological processing of antimony drugs. We have studied the complexation of the antileishmanial drug potassium antimony(III) tartrate to GSH in both aqueous solution and intact red blood cells by NMR spectroscopy and electrospray ionization mass spectrometry. The deprotonated thiol group of the cysteine residue is shown to be the only binding site for Sb(III), and a complex with the stoichiometry [Sb(GS)3] is formed. The stability constant for [Sb(GS)3] was determined to be log K 25 (I = 0.1 M, 298 K) based on a competition reaction between tartrate and GSH at different pH* values. In spite of being highly thermodynamically stable, the complex is kinetically labile. The rate of exchange of GSH between its free and Sb-bound form is pH-dependent, ranging from slow exchange on the 1H-NMR timescale at low pH (2 s-1 at pH 3.2) to relatively rapid exchange at biological pH (> 440 s-1). Such facile exchange may be important in the transport of Sb(III) in various biofluids and tissues in vivo. Our spin-echo 1H-NMR data show that Sb(III) rapidly entered red blood cell walls and was complexed by intracellular glutathione.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10951203     DOI: 10.1046/j.1432-1327.2000.01605.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  16 in total

Review 1.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 2.  Antimony transport mechanisms in resistant leishmania parasites.

Authors:  Frédéric Frézard; Rubens Monte-Neto; Priscila G Reis
Journal:  Biophys Rev       Date:  2014-01-25

3.  Glutathione-induced conversion of pentavalent antimony to trivalent antimony in meglumine antimoniate.

Authors:  F Frézard; C Demicheli; C S Ferreira; M A Costa
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

4.  Antimony-induced cardiomyopathy in guinea-pig and protection by L-carnitine.

Authors:  Marco Alvarez; Claire O Malécot; François Gannier; Jacques M Lignon
Journal:  Br J Pharmacol       Date:  2005-01       Impact factor: 8.739

5.  Reduction of pentavalent antimony by trypanothione and formation of a binary and ternary complex of antimony(III) and trypanothione.

Authors:  Siucheong Yan; Fei Li; Keyang Ding; Hongzhe Sun
Journal:  J Biol Inorg Chem       Date:  2003-06-21       Impact factor: 3.358

6.  Use of antimony in the treatment of leishmaniasis: current status and future directions.

Authors:  Arun Kumar Haldar; Pradip Sen; Syamal Roy
Journal:  Mol Biol Int       Date:  2011-06-08

7.  Sb(V) reactivity with human blood components: redox effects.

Authors:  Silvana López; Luis Aguilar; Luis Mercado; Manuel Bravo; Waldo Quiroz
Journal:  PLoS One       Date:  2015-01-23       Impact factor: 3.240

8.  Disrupting ROS-protection mechanism allows hydrogen peroxide to accumulate and oxidize Sb(III) to Sb(V) in Pseudomonas stutzeri TS44.

Authors:  Dan Wang; Fengqiu Zhu; Qian Wang; Christopher Rensing; Peng Yu; Jing Gong; Gejiao Wang
Journal:  BMC Microbiol       Date:  2016-11-25       Impact factor: 3.605

9.  Association of liposome-encapsulated trivalent antimonial with ascorbic acid: an effective and safe strategy in the treatment of experimental visceral leishmaniasis.

Authors:  Renata A O Castro; Neila M Silva-Barcellos; Carolina S A Licio; Janine B Souza; Míriam C Souza-Testasicca; Flávia M Ferreira; Mauricio A Batista; Denise Silveira-Lemos; Sandra L Moura; Frédéric Frézard; Simone A Rezende
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

10.  Synthesis and antileishmanial activity of antimony (V) complexes of hydroxypyranone and hydroxypyridinone ligands.

Authors:  Vafa Sheikhmoradi; Sedigheh Saberi; Lotfollah Saghaei; Nader Pestehchian; Afshin Fassihi
Journal:  Res Pharm Sci       Date:  2018-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.